Because adjuvant chemotherapy is of little benefit to patients at low risk of recurrence, this treatment is generally used for HR+/HER2− breast cancer patients considered at high risk of recurrence or for those with an unfavorable prognosis due to low HR expression and high cell proliferation26, 27. This evidence concerns the gene HR and breast carcinoma.